| IL-33 promotes food anaphylaxis in epicutaneously sensitized mice by targeting mast cells C Galand, JM Leyva-Castillo, J Yoon, A Han, MS Lee, ANJ McKenzie, ... Journal of Allergy and Clinical Immunology 138 (5), 1356-1366, 2016 | 234 | 2016 |
| Mechanical skin injury promotes food anaphylaxis by driving intestinal mast cell expansion JM Leyva-Castillo, C Galand, C Kam, O Burton, M Gurish, MA Musser, ... Immunity 50 (5), 1262-1275. e4, 2019 | 209 | 2019 |
| IL-23 induced in keratinocytes by endogenous TLR4 ligands polarizes dendritic cells to drive IL-22 responses to skin immunization J Yoon, JM Leyva-Castillo, G Wang, C Galand, MK Oyoshi, L Kumar, ... Journal of Experimental Medicine 213 (10), 2147-2166, 2016 | 99 | 2016 |
| ILC2 activation by keratinocyte-derived IL-25 drives IL-13 production at sites of allergic skin inflammation JM Leyva-Castillo, C Galand, S Mashiko, R Bissonnette, A McGurk, ... Journal of Allergy and Clinical Immunology 145 (6), 1606-1614. e4, 2020 | 92 | 2020 |
| Murine models of B‐cell lymphomas: promising tools for designing cancer therapies S Donnou, C Galand, V Touitou, C Sautès-Fridman, Z Fabry, S Fisson Advances in hematology 2012 (1), 701704, 2012 | 91 | 2012 |
| Cytokine profile in human eyes: contribution of a new cytokine combination for differential diagnosis between intraocular lymphoma or uveitis S Fisson, H Ouakrim, V Touitou, S Baudet, R Ben Abdelwahed, S Donnou, ... PloS one 8 (2), e52385, 2013 | 76 | 2013 |
| IL-22 derived from γδ T cells restricts Staphylococcus aureus infection of mechanically injured skin N Malhotra, J Yoon, JM Leyva-Castillo, C Galand, N Archer, LS Miller, ... Journal of Allergy and Clinical Immunology 138 (4), 1098-1107. e3, 2016 | 66 | 2016 |
| Mast cell–derived IL-13 downregulates IL-12 production by skin dendritic cells to inhibit the TH1 cell response to cutaneous antigen exposure JM Leyva-Castillo, M Das, E Artru, J Yoon, C Galand, RS Geha Journal of Allergy and Clinical Immunology 147 (6), 2305-2315. e3, 2021 | 51 | 2021 |
| Defective lymphoid organogenesis underlies the immune deficiency caused by a heterozygous S32I mutation in IκBα JL Mooster, S Le Bras, MJ Massaad, H Jabara, J Yoon, C Galand, ... Journal of Experimental Medicine 212 (2), 185-202, 2015 | 32 | 2015 |
| Th17 cells are involved in the local control of tumor progression in primary intraocular lymphoma C Galand, S Donnou, L Crozet, S Brunet, V Touitou, H Ouakrim, ... PLoS One 6 (9), e24622, 2011 | 31 | 2011 |
| Development of skin lesions in filaggrin-deficient mice is dependent on adaptive immunity S Leisten, MK Oyoshi, C Galand, JL Hornick, MF Gurish, RS Geha Journal of allergy and clinical immunology 131 (4), 1247-1250. e1, 2013 | 25 | 2013 |
| Immune adaptive microenvironment profiles in intracerebral and intrasplenic lymphomas share common characteristics S Donnou, C Galand, C Daussy, L Crozet, WH Fridman, ... Clinical & Experimental Immunology 165 (3), 329-337, 2011 | 22 | 2011 |
| Influence of tumor location on the composition of immune infiltrate and its impact on patient survival. Lessons from DCBCL and animal models C Galand, S Donnou, TJ Molina, WH Fridman, S Fisson, ... Frontiers in immunology 3, 98, 2012 | 19 | 2012 |
| Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy D Chand, DA Savitsky, S Krishnan, G Mednick, C Delepine, ... Cancer discovery 14 (12), 2407-2429, 2024 | 11 | 2024 |
| 470 Botensilimab, an Fc-enhanced CTLA-4 antibody, enhances innate and adaptive immune activation to promote superior anti-tumor immunity in cold and IO refractory tumors C Delepine, D Levey, S Krishnan, KS Kim, A Sonabend, M Wilkens, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 11 | 2022 |
| 377 AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects C Galand, V Venkatraman, M Marques, J Strauss, R Carvajal, M Lim, ... Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020 | 6 | 2020 |
| Fc-enhanced anti-CTLA-4 antibody, AGEN1181: new mechanistic insights for potent antitumor immunity and combination potential in treatment-resistant solid tumors AJ Tanne, C Galand, A Abou-Slaybi, M Wilkens, M Marques, S Ng, H Han, ... Cancer Research 81 (13_Supplement), 1878-1878, 2021 | 3 | 2021 |
| AGEN1571 is a novel high-affinity ILT2 antagonist antibody that promotes adaptive and innate immune responses O Udartseva, M Pupecka-Swider, P Garcia-Broncano, N Guo, S Campbell, ... Cancer Research 82 (12_Supplement), 2906-2906, 2022 | 2 | 2022 |
| 720 Fc-enhanced anti-CTLA-4 antibody, botensilimabms, enhances the efficacy of multiple therapeutic modalities in immunotherapy-refractory tumor models D Levey, KS Kim, A Sonabend, B Joshi, J Keith, J Allen, J Moore, H Han, ... Journal for ImmunoTherapy of Cancer 12 (Suppl 2), 2024 | | 2024 |
| AGEN2373 is a conditionally-active agonist antibody targeting the co-stimulatory receptor CD137 for the treatment of human malignancies C Galand, Y Xiao, C Mundt, B Morin, D Chand, C Riordan, ... Journal of Clinical Oncology 37 (15), 2019 | | 2019 |
Nidhi MalhotraBoston Children's Hospital/ Harvard Medical SchoolEmail verificata su childrens.harvard.edu